Ibiglustat

Drug Profile

Ibiglustat

Alternative Names: Genz-682452-AA; GZ-402671; GZ/SAR402671; SAR-402671

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Genzyme Corporation
  • Developer Sanofi Genzyme
  • Class Azabicyclo compounds; Carbamates; Small molecules; Thiazoles
  • Mechanism of Action Glucosylceramide synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Fabry's disease; Gaucher's disease; Parkinson's disease

Most Recent Events

  • 01 Dec 2016 Phase-II clinical trials in Parkinson's disease in USA (PO) (NCT02906020)
  • 01 Nov 2016 Phase-II clinical trials in Gaucher's disease in USA (PO) (NCT02843035)
  • 04 Oct 2016 Genzyme completes a phase II trial in Fabry's disease (Treatment-naïve) in USA, Czech Republic, France, Poland, Russia and the UK (NCT02228460)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top